MC-225 is under clinical development by MC2 Therapeutics and currently in Phase II for Vulvar Lichen Sclerosus. According to GlobalData, Phase II drugs for Vulvar Lichen Sclerosus does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MC-225 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MC-225 overview

MC-225 is under development for the treatment of uremic pruritus or chronic kidney disease-associated pruritus (CKD-AP), associated dry skin and vulvar lichen sclerosus. It is formulated as cream for topical administration. The drug candidate is a di-peptide being developed based on PAD (polyaphron dispersion) technology.

MC2 Therapeutics overview

MC2 Therapeutics is a privately held emerging pharmaceutical company. The company is headquartered in Hørsholm, Hovedstaden, Denmark.

For a complete picture of MC-225’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.